61 results on '"Torkko, Kathleen"'
Search Results
2. Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer
3. Supplementary Figure S2 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
4. Supplementary Table 1 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
5. Supplemental Figure 1 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
6. Supplementary Figure Legends from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
7. Supplemental Figure Legends. from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
8. Supplementary Table 1 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
9. Data from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
10. Supplemental Figure 4 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
11. Supplementary Table S2 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
12. Data from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
13. Data from Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
14. Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer
15. Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer
16. Supplemental Figure 3 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
17. Supplemental Figure 1 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
18. Supplementary Table 1 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
19. Data from Cooperative Dynamics of AR and ER Activity in Breast Cancer
20. Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
21. Supplemental Figure 2 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
22. Supplemental Figure 3 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
23. Data from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
24. Supplementary Figure S1 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
25. Supplementary Figure S2 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
26. Supplemental Figure Legends. from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
27. Supplementary Data from Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
28. Data from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
29. Supplementary Data from Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
30. Supplementary Table 1 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
31. Supplementary Methods from Cooperative Dynamics of AR and ER Activity in Breast Cancer
32. Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
33. Supplementary Figure Legends from Cooperative Dynamics of AR and ER Activity in Breast Cancer
34. Supplemental Figure 2 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
35. Supplementary Figure S3 from Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
36. Data from Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
37. Supplementary Figures 1-6 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
38. Supplemental Figure 4 from A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
39. Supplementary Tables 1-3 from Cooperative Dynamics of AR and ER Activity in Breast Cancer
40. Supplemental Table 1 from Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
41. Supplemental Figures S1-S11 from Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
42. Supplemental Table 1 from Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
43. Supplemental Figures S1-S11 from Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
44. Supplementary Figure 1 from The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
45. Data from The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
46. Supplementary Figure 1 from The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
47. Data from The HER4/4ICD Estrogen Receptor Coactivator and BH3-Only Protein Is an Effector of Tamoxifen-Induced Apoptosis
48. MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1
49. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer
50. Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.